Multiomics Identification of Novel Diagnostic Biomarkers and Precise Therapeutic Targets for Sepsis
International Journal of Clinical Practice · 2026-01 · 2026 (1)
DOI: 10.1155/ijcp/3132904 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Practice, online erschienen am 23.07.2026. Verfasst von Minqi Gu und 3 weiteren Autor:innen. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nantong Municipal Commission of Health and Family Planning.
Themen: Sepsis
Abstract (Originalsprache)
Background
Sepsis is characterized by life‐threatening organ dysfunction due to a dysregulated host response to infection. It lacks any specific treatment and is associated with a high mortality rate. Current biomarkers do not adequately capture the complex pathophysiology of sepsis. Therefore, this study integrates bioinformatics and reverses network pharmacology to identify key cell subpopulations, diagnostic biomarkers, and potential therapeutic compounds for treating sepsis.
Methods
We analyzed single‐cell RNA sequencing (scRNA‐seq) data (GSE175453) using Seurat, Monocle2, and CellChat for cell clustering, trajectory analysis, and intercellular communication. Differentially expressed genes (DEGs) were identified in the GSE134347 dataset. Functional annotations were performed on the core scRNA‐seq genes and genes shared with the DEGs. Reverse network pharmacology was used to predict natural compounds that target the shared genes, followed by molecular docking to evaluate their binding affinities. The expression of the candidate genes was then validated by qRT‐PCR using an external dataset (GSE95233), and their diagnostic performance was evaluated via ROC analysis.
Result
A total of 24 cell clusters were identified, with monocytes representing the key subgroup. Classical monocytes comprised the main subpopulation and the core of the differentiation trajectories. Cross‐analysis identified 14 shared genes, among which CYP1B1 and SLC2A3 were significantly upregulated in sepsis samples. ROC analysis suggests that CYP1B1 (AUC = 0.987) and SLC2A3 (AUC = 0.975) both hold excellent diagnostic value, as confirmed by qRT‐PCR and an external dataset (GSE95233). Reverse network pharmacology was used to construct a ‘target‐compound‐herbal medicine’ network consisting of two targets, ten compounds, and 42 herbal medicines. Based on the molecular docking results, the binding affinity of sanguinarine with CYP1B1 (−11.3 kcal/mol) was the strongest. Gene set enrichment analysis indicates that CYP1B1 correlates strongly with Toll‐like receptors, NOD‐like receptors, and PPAR signaling pathways.
Conclusion
Classical monocytes play a key role in sepsis pathogenesis. Both CYP1B1 and SLC2A3 are effective diagnostic biomarkers, and sanguinarine is a potential therapeutic agent targeting CYP1B1. These results provide a new perspective on potential diagnostic biomarkers and targeted immunotherapies for sepsis.
Förderung
- Nantong Municipal Commission of Health and Family Planning
Zitieren
APA
Gu, M., Chen, X., Tang, N., & Hu, X. (2026). Multiomics Identification of Novel Diagnostic Biomarkers and Precise Therapeutic Targets for Sepsis. International Journal of Clinical Practice, 2026(1). https://doi.org/10.1155/ijcp/3132904
Vancouver
Gu M, Chen X, Tang N, Hu X. Multiomics Identification of Novel Diagnostic Biomarkers and Precise Therapeutic Targets for Sepsis. International Journal of Clinical Practice. 2026;2026(1). doi:10.1155/ijcp/3132904
BibTeX
@article{Gu2026,
author = {Gu, Minqi and Chen, Xiang and Tang, Na and Hu, Xinyi},
title = {Multiomics Identification of Novel Diagnostic Biomarkers and Precise Therapeutic Targets for Sepsis},
journal = {International Journal of Clinical Practice},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/ijcp/3132904}
}
EUVIMED